CASE DISCUSSION
Approach to TTP
Presented from India by Dr. Sridatta Pawar0
Likes
1826
Views
73
Shares
91
Bookmarks
0
Credit Points
0
Learning Hours
0
CPD/CME Points
0
Courses Completed
Case Description
The approach to Thrombotic Thrombocytopenic Purpura (TTP) involves the prompt initiation of plasma exchange therapy to remove the circulating autoantibodies and replenish ADAMTS13 enzyme activity. Additionally, corticosteroids and immunosuppressive drugs are often administered to control the...
Case Summary
- Thrombotic Thrombocytopenic Purpura (TTP) is a rare disorder characterized by thromboses in small blood vessels, leading to thrombocytopenia and microangiopathic hemolytic anemia. It was first described in 1995 and its etiology remained unknown with fatal outcomes until the identification of the role of von Willebrand factor (vWF) in 1982, followed by the identification of ADAMTS13 in 2001. TTP is classified into acquired (mainly adult-onset) and inherited forms (childhood-onset), with the acquired form being more prevalent.
Speaker Profile
Dr. Sridatta Pawar
Consultant Nephrologist and Transplant Physician, GM hospitals, BangaloreDr. Sridatta Pawar, Consultant Nephrologist and Transplant Physician, GM hospitals, Bangalore
Disclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.